Abstract
INTRODUCTION

Many drugs are prescribed outside the terms of the marketing authorization ("off-label") from that approved by the health agency. Off-label use of drugs is relatively common in medical practice, even if it's often not supported by strong scientific evidence. Off-label therapy is defined as the use of medications for indications that is not mentioned in the approved labeling of the drug; using a drug outside of the recommended dosage range or duration of use; using a drug in certain unapproved
RESULTS
A total 852 scientific productions were identified, and 37 studies were selected by contain information about the off-label therapy in diabetic retinopathy.
We describe below the off-label drugs used for diabetic retinopathy. 26 . 27 . 28 . 29 
DISCUSSION
So the results of the studies support that the off-label treatment with intraocular steroids in diabetic patients, may prevent or delay the progression of diabetic retinopathy.
Fenofibrate
Fenofibrate is a drug of the fibrate class and is chemical name of propan-2-yl 2-{4-[(4-chlorophenyl) carbonyl]phenoxy}-2-methylpropanoate. It is a peroxisome proliferactor-activated receptor (PPAR)-agonist indicated for the treatment of hypertriglyceridemia and mixed dyslipidemia, and also has shown robust protective effects against diabetic retinopathy in DM2 patients
Moreover, it has been demonstrated that fenofibrate prevents the apoptosis of human retinal endothelial cells induced by serum deprivation through a PPAR-independent but AMP activated protein kinase-dependent pathway
Two trials indicated that fenofibrate has an anti-inflammatory and anti-atherosclerotic effect on the artery wall in addition to a lipid-modifying effect that may slow the progression of diabetic retinopathy, but the exact mechanisms underlying the beneficial effect on diabetic retinopathy remains uncertain
